Spots Global Cancer Trial Database for refractory anemia with ringed sideroblasts
Every month we try and update this database with for refractory anemia with ringed sideroblasts cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT00003123 | Myelodysplastic... | amifostine trih... | 17 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes | NCT00398047 | Leukemia Myelodysplastic... | Azacitadine and... | - 120 Years | Wake Forest University Health Sciences | |
| Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome | NCT00004208 | Myelodysplastic... | ATG + CSA Supportive care | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Gemtuzumab in Treating Patients With Myelodysplastic Syndrome | NCT00022321 | Myelodysplastic... | gemtuzumab ozog... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Paricalcitol in Treating Patients With Myelodysplastic Syndrome | NCT00064376 | Leukemia Myelodysplastic... | paricalcitol | 25 Years - 100 Years | Cedars-Sinai Medical Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00119366 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo... | iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom... | 16 Years - 50 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00003959 | Leukemia Myelodysplastic... | ras peptide can... sargramostim | 17 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002798 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan | - 21 Years | National Cancer Institute (NCI) | |
| Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01146210 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00008177 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Untreated Adult... | iodine I 131 mo... total-body irra... allogeneic hema... peripheral bloo... fludarabine pho... cyclosporine mycophenolate m... laboratory biom... | 50 Years - | Fred Hutchinson Cancer Center | |
| S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00016419 | Leukemia Myelodysplastic... | anti-thymocyte ... cyclosporine | 15 Years - | SWOG Cancer Research Network | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes | NCT00104962 | Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi... | lenalidomide | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome | NCT00731328 | Leukemia Myelodysplastic... Nonmalignant Ne... Paroxysmal Noct... | nonmyeloablativ... | - 75 Years | Asan Medical Center | |
| Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | NCT00003681 | Anemia Myelodysplastic... | epoetin alfa amifostine trih... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome | NCT00513578 | Myelodysplastic... | PR1 leukemia pe... incomplete Freu... sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan in Treating Patients With Myelodysplastic Syndrome | NCT00003675 | Leukemia Myelodysplastic... | topotecan hydro... | 15 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Decitabine in Treating Patients With Myelodysplastic Syndrome | NCT00003361 | Leukemia Myelodysplastic... | decitabine | 15 Years - | National Cancer Institute (NCI) | |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes | NCT00104962 | Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi... | lenalidomide | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Decitabine in Treating Patients With Myelodysplastic Syndrome | NCT00003361 | Leukemia Myelodysplastic... | decitabine | 15 Years - | National Cancer Institute (NCI) | |
| Bortezomib in Treating Patients With Myelodysplastic Syndromes | NCT00262873 | Myelodysplastic... | bortezomib | 18 Years - | University of Rochester | |
| Tipifarnib in Treating Patients With Myelodysplastic Syndromes | NCT00005845 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... | tipifarnib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00005853 | Leukemia Myelodysplastic... | anti-thymocyte ... etanercept | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00005853 | Leukemia Myelodysplastic... | anti-thymocyte ... etanercept | - | Fred Hutchinson Cancer Center | |
| Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers | NCT00619645 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... peripheral bloo... | 18 Years - 120 Years | University of California, Davis | |
| Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | NCT00003681 | Anemia Myelodysplastic... | epoetin alfa amifostine trih... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | NCT00004145 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 60 Years | University of Chicago |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
